Compare DFNS & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFNS | NMTC |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 30.6M |
| IPO Year | N/A | 2010 |
| Metric | DFNS | NMTC |
|---|---|---|
| Price | $0.31 | $3.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.90 |
| AVG Volume (30 Days) | ★ 4.1M | 33.6K |
| Earning Date | 04-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $0.30 | $0.55 |
| 52 Week High | $2.68 | $5.40 |
| Indicator | DFNS | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 41.44 |
| Support Level | N/A | $0.69 |
| Resistance Level | $0.51 | $4.87 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 1.10 | 5.65 |
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.